Bluetongue (BT) is a serious hemorrhagic disease of ruminants caused by bluetongue virus (BTV). Inactive BTV vaccines have been successful in field trials in some areas, and inactivated vaccines are considered safer. However, information about the effect of the viral antigen level on the serological response and efficiency of the inactive BTV-16 vaccine is lacking. In the present study, the serological response and efficiency of the viral antigen concentration in the binary ethylenimine-inactivated Chinese BTV serotype-16 vaccine were investigated. The viral antigens in the viral suspension (VS) were quantified using a modified BTV AC-ELISA method. Four batches of vaccine containing 1, 5, 10, and 50 μg/ml of viral antigen were generated from the VS. Four groups of naïve Chinese sheep were vaccinated with the different vaccine batches, and the serological response and vaccine efficiency were investigated before and after challenge infection. The vaccines containing 10 and 50 μg/ml of viral antigen induced significant ELISA and neutralizing antibody titers 14 days after vaccination, whereas the vaccines containing 1 and 5 μg/ml of viral antigen did not have these effects. A booster immunization at 21 days enhanced all groups' antibody titers; however, the increased titer was related to the viral antigen level. In contrast to the serological response, the viral antigen level of the vaccines did not have a significant effect on the vaccine efficiency. With the exception of one sheep from the 5 μg/ml viral antigen group, all vaccinated sheep from the four antigen level groups showed strong resistance to infection based on their clinical symptoms, rectal temperatures and viremia. Collectively, these data suggested that viral antigen levels from 1 to 50 μg/ml *These authors contributed equally to the work. 
Introduction
Bluetongue (BT) is a serious hemorrhagic disease of ruminants caused by bluetongue virus (BTV). BTV is a non-contagious arthropod-borne viral pathogen that is a member of the Orbivirus genus and Reoviridae family [1] [2] . Currently, 26 serotypes have been identified worldwide [3] . A total of 13 BTV serotypes exist in BTV-enzootic areas of Yunnan province in China based on viral isolation and neutralization studies [4] . Serological investigations showed that BTV-16 was the dominant strain in the BTV-enzootic areas. BT mostly causes a mild disease or no obvious disease in the BTV-enzootic areas of Yunnan. However, a few serious disease cases have been identified. These serious cases are characterized by fever, facial edema, ulceration of the oral mucosa, congestion of the tongue and coronary band, debility, decreased production and variable mortality [2] . Recently, invasion of BTV in Mediterranean Europe and BTV-8 epizootics in Western and Central Europe has caused significant economic losses [5] [6] .
BT is considered a re-emerging arboviral disease of ruminants in many countries [7] [8] [9] . Due to the importance of BT in China, the Chinese Ministry of Agriculture has launched programs on BT to study its prevention and control. Yunnan province is located in the southwest of China. The complicated nature and geographical environment of this province have resulted in closely linked BTVenzootic areas and BTV-free areas, which enhance the risk of cross-region BTV infection. From this perspective, the development of a BTV-16 vaccine that is effective against BTV infection for use in Yunnan province is essential.
Inactivated monovalent vaccines against BTV-2, -4, -8 and -16 have been used successfully in field trials [7] [10] [11] [12] . Inactivated vaccines are considered safer, and various risks have been associated with the use of live vaccines [13] .
However, only low levels of specific antibodies are detected by C-ELISA, and nearly no virus neutralizing antibodies are observed in vaccinated sheep following the use of inactivated vaccines [12] [14] . Conversely, live attenuated BTV vaccines have been shown to induce effective and lasting immunity in sheep [9] ; for instance, a modified live vaccine induced 98% of cattle to produce neutralizing antibodies one month after a single shot [15] . Moreover, a four-fold vaccine overdose in the cattle led to significantly higher C-ELISA antibody titers, and neutralizing antibodies could be detected as early as four weeks after the first vaccination [16] ; this result indicates that the viral antigen level is important to the antibody response. However, the exact relationship between the viral antigen level and the serological response has not been reported. Antibodies are important for the prevention of BTV infection, and a negative correlation between the presence of neutralizing antibodies at the time of challenge infection and the subsequent incidence of clinical signs and viremia has been reported [17] . Furthermore, antibody analysis is useful under field conditions because evaluation of the immune response is limited to humoral immunity after millions of animals have been vaccinated [16] . Reports have indicated that the presence of neutralizing antibodies does not always correlate with the degree of protection [12] . These observations indicate that the vaccine should be judged by challenge infections rather than antibody analysis. However, information about the relationship between the antigen level and vaccine efficiency is lacking. The OIE manual has suggested the use of chromatography-purified and concentrated BTV antigens in vaccines via dilution in a buffer solution and the addition of adjuvants [1] . Therefore, knowledge of the relationship between the viral antigen and serological response and between the viral antigen and vaccine efficiency could be useful.
In the current study, the viral antigen level of the binary ethylenimine (BEI)-inactivated oil-adjuvanted BTV-16 vaccine was determined via an AC-ELISA method. Vaccines containing viral antigen concentrations ranging from 1 to 50 μg/ml were used to investigate the relationships between the viral antigen levels and the serological response and between the viral antigen levels and the vaccine efficiency.
Material and Methods

Animals
Thirty healthy 1.5-2-year-old naïve sheep weighing approximately 40 kg were purchased from the BT-free area (Xundian sheep breeding farm, Yunnan). The animals tested sero-negative by sero-neutralization (SNT) using BHK21 cells.
The animals were randomly divided into five groups of 6 animals each, including four vaccine groups and one control group. All animals were maintained in insect-proof sheds. The experiments were performed in accordance with the research and ethical review committees of Yunnan Veterinary and Animal Science Institute.
Virus
BTV-16/DH/2015 is a BTV serotype 16 strain isolated from the blood of cattle in Dehong county of Yunnan province in 2015. A BHK21 virus passaged six times was used for the vaccine. A blood sample containing the same strain without passage in any cell line was injected into sheep to amplify the virus. Heparinized blood from the infected sheep was collected 7 days post-inoculation (dpi) and used for the challenge study. The infected blood used for the challenge was titrated by inoculation into embryonating chicken eggs (ECEs). The method used for titration was also used for the viremia analysis.
Quantification of Viral Antigens in the Viral Suspension (VS)
The viral antigens in the VS was quantified by comparison with purified BTV-16 antigen in a modified AC-ELISA. The purified BTV-16 antigens used for the comparison were collected from the 58% -60% sucrose gradient after centrifugation of the pre-condensed virus at 28,000 rpm with an sw40 rotor (Beckman, USA) for 4 h. The purity of the purified BTV was verified by SDS-PAGE (10%), and the viral protein concentration was determined by the BCA method according to the manufacturer's protocol.
The AC-ELISA method used for the quantification is briefly described below.
An ELISA plate (Costar, USA) was coated with a polyclonal goat-anti-BTV an- 
BEI-Inactivated BTV-16 Vaccine Preparation and Immunization of Sheep
The BEI-inactivated BTV-16 vaccine was prepared as previously described [10] .
Briefly, BTV-16-infected BHK21 cells were harvested when they showed 90% cytopathic effects. The suspension was freeze-thawed, sonicated and centrifuged to obtain the supernatant. A virus suspension with a titer greater than 10 M sodium thiosulfate at 4˚C, with a final concentration of 0.1 M at the end of the incubation period. Following the sterility and innocuity tests [10] , the whole viral antigen content in the viral suspension (VS) was determined by ELISA as described above. Then, the VS was diluted or concentrated to 1, 5, 10 and 15 μg of viral antigen/ml. The vaccine was adjuvanted by mixing thoroughly with an equal volume of an emulsifying agent (mineral oil, 2% Tween-80, and 1% thimerosal).
The sheep were divided into five groups (N = 6 per group); four groups were immunized and one group was the control. Each immunized group received 1 ml of BEI-inactivated oil-adjuvanted BTV-16 vaccine with different viral antigen levels (1, 5, 10 and 15 μg of viral antigen/ml). An equal quantity of vaccine was inoculated into the neck and posterior thigh by the intramuscular route. All vaccinated animals were re-vaccinated on the 21st day with a similar dose and route. The control group received PBS.
Serology
C-ELISA and SNT were used to survey the BTV antibody development of the immunized sheep. The C-ELISA was performed as previously described [1] .
Briefly, a 96-well microplate was coated with sonicated cell culture antigen at 4˚C overnight. Then, a serogroup-reactive anti-VP7 Mab was used as the competition antibody to compete with the sheep antibodies. Based on the recommended cut-off values, the samples were interpreted as positive if they showed an OD value less than 50% of the negative control. Sheep serum was diluted two-fold from 1/2 to 1/256 for the C-ELISA procedure. The titers were expressed as the final dilution of serum present in the dilution where 50% of the wells were positive.
The SNT was performed as follows. Starting from a 1:4 dilution, the sera were diluted in a two-fold dilution series across the plate using at least two rows of wells per serum sample in a 50 μl volume. Approximately 100 TCID50 (50% tissue culture infective dose) of the BTV-16 virus was added in a 50 μl volume and mixed with the diluted serum. Approximately 10 4 cells were added per well in a 100 μl volume. After incubation for 4 -6 days, the results were read using an inverted microscope. The wells were scored for the degree of CPE observed. The titers were expressed as the final dilution of serum present in the serum/virus mixture where 50% of the wells were protected.
Challenge
The BTV-16 strain used in the study for the challenge infection was not passaged in any isolation system, which might induce a clinical BT disease milder than the natural disease. The virus retained moderate virulence as observed from the pilot study. Seven days after re-vaccination, both the immunized and naive groups were challenged by intradermal inoculation of 2 ml of infected blood containing 
Clinical Observations
The average clinical scores (ACS) were previously described and were used with a few modifications [10] [18] . From 1 -14 dpi, the ACSs of the challenged animals were calculated for fever, mouth lesions, foot lesions and respiratory signs.
The details are given below:
(a) Fever score-fever readings above 40˚C from 2 to 14 dpi were taken as the cumulative total for each animal and averaged to obtain the fever ACS.
(b) Mouth lesion score-mouth lesions were scored on a scale of 0 -4 in each animal depending on the severity and averaged to obtain the mouth ACS.
(c) Foot lesion score-foot lesions were scored on a scale of 0 -4 in each animal depending on the severity and averaged to obtain the foot ACS.
(d) Respiratory score-nasal discharge (serous to bloody discharge) and respiratory distress were scored on a scale of 0 -4 depending on the severity and averaged to obtain the respiratory ACS.
Viremia Analysis
Viremia Analysis by Titration of Infected Blood
Heparinized blood collected aseptically from each sheep was briefly titrated through ECEs. The ECEs were inoculated with a series of 10-fold dilutions of infected blood. The chicken embryos were incubated for 7 days at 33.5˚C. Tissues from the embryos that died between 2 and 7 dpi were collected, and the presence of BTV was confirmed using a Bluetongue antigen capture ELISA (BTACE) based on a monoclonal antibody to the BTV core protein VP7 [19] .
The results were expressed as the chicken embryo infections dose (CEID50), which was calculated using the method of Reed and Muench [20] . BTV RNA in the blood was quantified using previously described methods [22] .
Quantification of BTV
Total BTV-16 RNA was extracted from infected BHK-21 cells with viral titers greater than 10 6 TCID50 (50 μl). Cellular ssRNA was removed with 2 M LiCl [23] [24] to obtain pure viral dsRNA, which was analyzed by spectrophotometry.
A total of 1 μg of purified BTV RNA was converted to cDNA using random primers with the Reverse Transcription System (Promega, USA) and used for standard dilution curve preparation. Ten-fold serial dilutions of known copies of cDNA and their corresponding CT values were used to generate a standard log 10 dilution curve with a correlation coefficient of 0.97. An increase of 2.0 cycles for every log 10 decrease of input RNA was shown based on the slope of the regression line. Quantification was accomplished by comparing the CT values of each test sample with the standard curve drawn on the same reaction.
Statistical Analysis
All statistical analyses were performed with SPSS 17.0. The log10 of the viral antigen dilution and the OD reading were analyzed by linear-regression analysis to generate a linear equation. The results of the viremic titers in the naive and immunized animals were compared using a non-parametric Mann-Whitney test. A P-value < 0.05 was considered significant.
Results
Quantification of Viral Antigens in the VS
The 
Viral Antigen Level and Serological Response
Sera from the immunized and control animals were collected weekly after the cut off titer value (titer ≥ 4 for C-ELISA and titer ≥ 3 for SNT), which was calculated as the mean titer ± 3 SD of the negative sera (n = 60).
groups (P > 0.05). The antibody response of the animals in the 1 μg/ml and 5 μg/ml groups was diverse, with some animals not exhibiting a significant antibody response even after the second vaccination ( Table 2 ). The booster immunization 21 days after the first immunization enhanced the ELISA and SNT antibody titers in the 4 groups. However, the boosted ELISA and SNT titers of the 1 μg/ml group were significantly lower than the titers in the other groups (P < 0.01), and no difference was detected in the boosted SNT titers of the 10 and 50 μg/ml groups.
Viremia Analysis in Challenge Infection
The viremia of all immunized groups in the challenge infection was assessed by virus inoculation and qRT-PCR. Sero-negative sheep were immunized twice at 3 week intervals and challenged with homologous BTV-16. The virus inoculation results were expressed as CEID50 by inoculation of ECEs with a series of whole blood dilutions, and the viral RNA copies in the same blood samples were monitored by BTV qRT-PCR. The CEID50 and viral copies of the control sheep were significantly higher (P < 0.01) from 4 to 16 dpi compared to the immunized sheep ( Table 3, Table 4 ). Exceptionally, one control sheep maintained an undetectable CEID50 during the experiment, although viral RNA was detected from 4 DPI. Conversely, immunized sheep from the 1, 10, and 50 μg/ml antigen level groups showed viral titers and viral RNA copies below the detection limit during the test period. Only one immunized sheep from the 5 μg/ml group had a detectable viral titer and viral RNA copies from 4 to 16 DPI; this animal also had rising temperature, but with no other clinical symptoms were observed. No obvious relationship was found between the antigen level and viremia.
Clinical Disease Analysis in Challenge Infection
Following challenge, the animals in the naive and four antigen level vaccine Table 2 . Number of animals with C-ELISA and SNT titers above the cut-off (1/16 and 1/8). 
Discussion
BTV-16 is the dominant strain that is prevalent in BTV-enzootic areas of China.
Although mild to moderate BT disease has been observed in local sheep asso- Low levels of antibodies in the serum samples of cattle and sheep are associated with the use of inactive vaccines [9] [15]. However, an increase in the vaccine dose in cattle clearly led to higher ELISA titers [16] , indicating that a higher viral antigen level could induce a better serological response. In the study, we used vaccines containing 1 to 50 μg/ml of antigen and showed that the vaccine with the 1 μg/ml antigen level poorly induced antibody production, the 5 μg/ml antigen level induced intermediate antibody production, and the 10 and 50 μg/ml antigen levels induced good ELISA and SNT antibody results. No difference was observed between the vaccines with the 10 and 50 μg/ml antigen levels.
A boost immunization was useful for improving the antibody level, but the boost in antibody production in the 1 μg/ml antigen level group was still significantly lower compared with the other groups.
Neutralizing antibodies are important for the prevention of BT disease. A negative correlation was found between the presence of neutralizing antibodies at the time of challenge infection and the subsequent incidence of clinical signs and viremia [17] . Other studies showed that the presence of neutralizing antibodies did not always correlate with the degree of protection [12] . Vaccine-induced protection was also observed in the absence of detectable BTV neutralizing antibody levels [25] . A similar observation was found in this study. The vaccine containing 1 μg/ml of viral antigen poorly induced neutralizing antibodies but provided good protection for the animals against the challenge infection. This result may be due to specific cellular involvement in the defense against BTV, with the ability to cross-protect against other serotypes [23] [26] . However, the cross-protection by the specific cellular response may have been related to conserved proteins such as NS1 and thus only contributed partial protection. For more efficient protection, more specific neutralizing antibodies may be needed.
In our study, a sheep from the 5 μg/ml antigen level group failed in the challenge infection, which might indicate that a higher antibody titer was needed. The failure of one sheep in the challenge infection did not represent statistical significance compared with the other groups; however, a vaccine containing a viral antigen concentration greater than 10 μg/ml may be better to avoid random immune failure and achieve a better antibody response.
OIE suggests purification should be used in inactive vaccine preparation [1] .
This procedure is performed by chromatography; then, the inactivated virus is concentrated by ultrafiltration and stored before proceeding to vaccination.
Chromatography is a good method but requires expensive equipment, which makes this approach impossible in many laboratories. ELISA quantification has been used for other viruses [27] . This method has good repeatability and reliability. However, because ELISA quantification is an indirect method, other factors should be considered in the quantification procedure. Importantly, the purity of the standard antigen used for comparison has a huge influence on the quantification accuracy. In this study, the BTV antigen was purified through a continuous sucrose gradient, and the purity was demonstrated by SDS-PAGE to have possibly improved the level of accuracy.
Conclusion
The development of vaccines that are easy to standardize through antigenic quantification would offer a better strategy for improving regional protection against BTV infection. A vaccine with sufficient antigen to induce neutralizing antibodies is likely to provide better protection against the infection. Although further evaluation of the vaccine is required under field conditions, the present findings suggest that viral antigen levels from 1 to 50 µg/ml in an inactive BTV-16 vaccine have a significant effect on the serological response. The vaccine containing 1 µg/ml was sufficient to induce high protection; however, to obtain a better serological response, we recommend using a vaccine with more than 10 µg/ml of viral antigen.
